World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
40803
World Ranking
8847
National Ranking
4557

Overview

Andrew Blauvelt is affiliated with the Veterans Health Administration in the United States. Their research primarily focuses on Medicine and Immunology and Microbiology, with a significant emphasis on Immunology, Dermatology, Immunology and Allergy, Physiology, and Pediatrics, Perinatology and Child Health as key subfields.

The scientist's work concentrates on major topics such as psoriasis treatment and pathogenesis, dermatology and skin diseases, asthma and respiratory diseases, pharmaceutical studies and practices, health systems including economic evaluations and quality of life, food allergy and anaphylaxis research, and autoimmune bullous skin diseases.

Andrew Blauvelt's notable recent papers include:

  • Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis, 2021, JAMA Dermatology
  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials, 2021, The Lancet
  • Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2), 2020, British Journal of Dermatology
  • Bimekizumab versus Secukinumab in Plaque Psoriasis, 2021, New England Journal of Medicine
  • Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis, 2020, JAMA Dermatology

Frequent co-authors in their research include Mark Lebwohl, Kim Papp, April W. Armstrong, Melinda Gooderham, and Eric L. Simpson.

The scientist frequently publishes in journals such as the Journal of the American Academy of Dermatology, SKIN The Journal of Cutaneous Medicine, British Journal of Dermatology, Journal of Investigative Dermatology, and Dermatology and Therapy. These venues reflect a strong concentration on dermatology and skin-related medical research.

Best Publications

  • Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

    Eric L. Simpson;Thomas Bieber;Emma Guttman-Yassky;Lisa A. Beck

  • Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  • Human skin Langerhans cells are targets of dengue virus infection.

    Shuenn-Jue L. Wu;Geraldine Grouard-Vogel;Wellington Sun;John R. Mascola

  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    Andrew Blauvelt;Kim A. Papp;Christopher E.M. Griffiths;Bruce Randazzo;Bruce Randazzo

  • Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Kenneth B Gordon;Jean-Frederic Colombel;Dana S Hardin

  • Circulating Th17, Th22, and Th1 cells are increased in psoriasis.

    Shinji Kagami;Heather L. Rizzo;Jennifer J. Lee;Yoshinobu Koguchi

  • IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice

    John S. Cho;Eric M. Pietras;Nairy C. Garcia;Romela Irene Ramos

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Diamant Thaçi;Andrew Blauvelt;Kristian Reich;Tsen-Fang Tsai

  • Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Kenneth B Gordon;Bruce Strober;Mark Lebwohl;Matthias Augustin

  • Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Kristian Reich;Kim A Papp;Andrew Blauvelt;Stephen K Tyring

  • Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

    A. Wollenberg;A. Blauvelt;E. Guttman‐Yassky;M. Worm

  • Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis.

    Erin G. Harper;Changsheng Guo;Heather Rizzo;Joseph V. Lillis

  • Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.

    Kim A. Papp;Andrew Blauvelt;Michael Bukhalo;Melinda Gooderham

  • Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection

    M Zaitseva;A Blauvelt;S Lee;C K Lapham

  • Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

    Eric L. Simpson;Amy S. Paller;Elaine C. Siegfried;Mark Boguniewicz

  • Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5

    Michael M Lederman;Ronald S Veazey;Robin Ewart Offord;Donald E Mosier

  • Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines.

    Erin Fitch;Erin Harper;Iliyana Skorcheva;Stephen E. Kurtz

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection

    John Cho;Eric Pietras;Nairy Garcia;Romela Irene Ramos

Frequent Co-Authors

Kim Papp
Kim Papp Probity Medical Research
Kristian Reich
Kristian Reich University of Göttingen
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Craig L. Leonardi
Craig L. Leonardi Saint Louis University
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Diamant Thaçi
Diamant Thaçi University of Lübeck
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester
Eric L. Simpson
Eric L. Simpson Oregon Health & Science University
Neil M.H. Graham
Neil M.H. Graham Regeneron (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative career pathways in healthcare is becoming increasingly accessible with the rise of online degree programs. Students who want to pursue a medical career but may not follow the traditional MD route have a variety of affordable and flexible options to consider.

For those interested in healthcare administration and technology, a health information technology online degree offers a path into a growing field focused on the management of patient data. Similarly, students looking for entry-level roles in healthcare can explore the medical billing and coding online courses cost to find budget-friendly ways to get certified remotely.

Nursing remains a popular and rewarding option. There are a range of online nurse practitioner programs that allow registered nurses to advance their qualifications fully online. Aspiring RNs can also benefit from the cheapest rn to bsn online programs to boost credentials affordably and conveniently.

Each of these pathways provides students with a flexible and cost-effective way to enter or advance in the healthcare sector, making them excellent alternatives or complements to traditional medical studies.

Best Scientists Citing Andrew Blauvelt

Trending Scientists

Recently Published Articles